Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial

Yu Hong Chen,Chien-Ning Huang,Young Min Cho,Pengfei Li,Liqun Gu,Feng Wang,Jun Yang,Wei Qing Wang

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial

2018

Yu Hong Chen
Chien-Ning Huang
Young Min Cho
Pengfei Li
Liqun Gu
Feng Wang
Jun Yang
Wei Qing Wang

Aims To compare the efficacy and safety of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide 1.5 and 0.75 mg with glimepiride in East‐Asian patients with type 2 diabetes (T2D).

Keywords:

Glucagon-like peptide 1 receptor
Endocrinology
Dulaglutide
Diabetes mellitus
Glimepiride
Type 2 diabetes
Internal medicine
Medicine
Active Comparator
Confidence interval
Tolerability
Nausea
Gastroenterology
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations